Table 1.
Baseline characteristics of people with cystic fibrosis recruited in this study
| Baseline Characteristics | |
|---|---|
| n | 25 |
| Male % | 13 (52%) |
| Age | 13 (7–58) |
| Spirometry | |
| ppFEV1 | 94% (61%–123%) |
| ppFVC | 101% (74%–128%) |
| ppFEF25-75 | 74% (30%–120%) |
| ppFEF75 | 75% (23%–141%) |
| MBWShX | |
| LCI2.5 | 6.9 (5.8–22.8) |
| LCIShX | 8.1 (5.9–30.5) |
| UVLU | 0.8 (0.1–8.6) |
| Volume of trapped gas (VTG) | |
| 5IC VTG/RV | 2.8% (0.1%–12.4%) |
| 5VC VTG/RV | 4.4% (0.1%–14.9%) |
| Body plethysmography | |
| RV/TLC% | 25.8% (19.0%–43.4%) |
| FRCPleth-FRCMBW/RV % | 43.95% (1.3%–104%) |
| Spiro-CT | |
| Airway disease score % | 2.3% (0.3%–12.2%) |
| Bronchiectasis % | 1.7% (0%–9.4%) |
| Mucus plugging % | 0% (0%–2.7%) |
| Trapped air % | 14.9% (0%–46.1%) |
5IC, 5 inspiratory capacity breaths; 5VC, 5 vital capacity; FRC, functional residual capacity; LCI, lung clearance index; MBWShX, Short extension multiple breath washout; ppFEF25–75%, percent predicted forced expiratory flow at 25–75% of the forced vital capacity (FVC); FEF75%, percent predicted forced expiratory flow when 75% of FVC has been exhaled; ppFEV1, percent predicted forced expiratory volume in 1 second; ppFVC, percent predicted forced vital capacity; RV, residual volume; Spiro-CT, spirometry-controlled computed tomography; TLC, total lung capacity; UVLU, under-ventilated lung units; VTG, volume of trapped gas.